Flip 2 coins. This attack does 20 more damage for each heads.
Your opponent's Active Pokémon is now Poisoned. That Pokémon can't retreat during your opponent's next turn.
XY was released in 2014. XY is grouped under the XY era.
The checklist contains 146 cards, placing it in a mid-size expansion range. As of 2026, the set is 12 years old and now falls into an established back-catalog period.
Scolipede (#53) is one of the Rare prints in this expansion.
Scolipede appears in XY, released in 2014. Card flavor text reads: "It clasps its prey with the claws on its neck until it stops moving.
Then it finishes it off with deadly poison." Core profile: Its card type is Pokémon. The rarity label is Rare.
Printed HP is 150. Energy typing is Psychic.
Scolipede evolves from Whirlipede. Attack line includes "Random Peck" and "Poison Ring".
Latest market snapshots place Scolipede in XY at roughly $0.42. Week-over-week change is limited (0.0%), indicating short-term stability.
Current value is elevated versus the 30-day mean ($0.41), by 3.0%. The 90-day window shows a floor near $0.25 and a peak around $0.43 (43% total spread), which maps to moderate-volatility movement.
Rarity classification for this copy is Rare.
Collectors tracking Scolipede often benchmark it against other Scolipede cards. The current sample spans 6 comparable cards from 5 sets.
Observed alternatives run from $0.10 to $19.48 (19380% spread). The current card sits -89% versus the sampled alternative average of $3.99.
Notable alternatives include Scolipede #56 (Black Bolt) at $0.21, Scolipede #134 (Black Bolt) at $19.48, Scolipede #107 (Chilling Reign) at $0.15, and Scolipede #117 (Twilight Masquerade) at $0.10.
Market structure summary: Weekly drift is minimal (0.0%), indicating a relatively balanced short-term market. Observed 90-day bounds of $0.25 and $0.43 create a 43% band, matching a moderate-volatility profile.
Current value is 3.0% above its 30-day reference ($0.41). This sample does not include a stable graded benchmark, which means active listings remain the best condition-adjusted reference.
